Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Addex Therapeutics Ltd. files with the SEC in its annual reports.
In CHF millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
6.04
2.76
3.61
2.92
1.42
1.61
0.4
Research and development
2.63
4.92
12.5
10.4
12.8
8.24
1.19
0.85
Operating income
-3.24
-1.42
-14.6
-12.2
-15.5
-10.5
-2.24
-2.76
Interest expense
0.05
0.22
0.21
0.65
0.06
0.29
0.32
0
Interest income
0.04
0.04
0.22
0.03
0.06
0.03
Pre-tax income
-3.28
-1.64
-14.8
-12.9
-15.4
-10.8
-2.5
-4.91
Income tax
0
0
0
0
0
0
0
Income from continuing operations
-10.8
-2.5
-4.91
Net income
-3.28
-1.64
-14.8
-12.9
-15.4
-20.8
-10.6
7.06
EPS, basic
-0.25
-0.07
-0.56
-0.48
-0.45
-0.46
-0.14
0.07
EPS, diluted
-0.25
-0.07
-0.56
-0.48
-0.45
-0.46
-0.14
0.07
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
2.58
31.5
31.5
18.7
20.5
6.96
3.87
3.34
Receivables
0.27
0.12
0.07
0.16
0.42
0.11
0.02
Total current assets
42.2
32.4
19.5
21.9
7.83
4.23
3.54
Property, plant and equipment
0
0.01
0.03
0.07
0.07
0.04
0.02
0
Lease right-of-use assets
0.54
0.57
0.47
0.36
0.33
0.04
Total assets
42.2
33
20.2
22.5
8.28
4.64
10.7
Accounts payable
2.12
4.2
2.49
3.85
3
2.38
0.79
Total current liabilities
2.33
5.68
3.62
4.13
3.28
2.89
0.8
Lease liabilities
0.18
0.26
0.19
0.09
0.07
0.03
Total liabilities
2.97
7.5
5.57
5.61
3.37
3.5
1
Paid-in capital
286
286
287
284
270
266
266
Retained earnings
-286
-301
-314
-329
-350
-360
-353
Total equity
1.34
39.2
25.5
14.6
16.9
4.91
1.15
9.68
Total liabilities and equity
42.2
33
20.2
22.5
8.28
4.64
10.7
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-3.28
-1.64
-14.8
-12.9
-15.4
-20.8
-10.6
7.06
Cash from operations
-2.14
1.75
-9.48
-12.2
-14.7
-16.4
-7.99
-5.37
Capital expenditures
-0
-0.01
-0.03
-0.06
-0.03
-0
-0.01
-0
Cash from investing
-0
-0.06
-0.04
-0.06
-0.03
0
-0.01
4.65
Stock issued
40.5
10.2
Cash from financing
3.36
37.4
-0.46
0.05
16.4
3.1
5.26
0.1
Exchange rate effect
-0.05
0.01
-0.14
-0.65
0.12
-0.2
-0.36
0.1
Free cash flow
-2.14
1.74
-9.51
-12.2
-14.7
-16.4
-8
-5.37
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Operating margin
-681.8%
Operating income / revenue.
Pre-tax margin
-1,215.0%
Pre-tax income / revenue.
Net margin
1,746.0%
Net income / revenue.
FCF margin
-1,330.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-1,330.0%
Cash from operations / revenue.
Return on assets (ROA)
92.1%
Net income / average total assets.
R&D / revenue
211.4%
Research and development expense / revenue.
Capex / revenue
0.3%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-74.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-48.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-31.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
130.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-22.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-20.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.42x
Current assets / current liabilities.
Quick ratio
4.19x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.17x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
9.4%
Total liabilities / total assets.
Interest coverage
-777x
Operating income / interest expense.
Working capital
CHF 2.7M
Current assets - current liabilities.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.05x
Revenue / average total assets.
Fixed asset turnover
34.1x
Revenue / average property, plant and equipment.
Receivables turnover
6.42x
Revenue / average receivables.
Days sales outstanding
57 days
365 x average receivables / revenue.
FCF conversion
-76.2%
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
CHF 0.07
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
CHF 0.07
Net income per basic share, as reported (split-adjusted).
What was Addex Therapeutics Ltd.'s revenue in fiscal 2024?
Addex Therapeutics Ltd. reported revenue of CHF 404.1K for fiscal 2024, 74.9% lower than the year before.
Was Addex Therapeutics Ltd. profitable in fiscal 2024?
Yes. Net income was CHF 7.1M, a net margin of 1,746%.
How much free cash flow did Addex Therapeutics Ltd. generate in fiscal 2024?
Cash from operations of CHF 5.4M minus capital expenditures of CHF 1.3K left free cash flow of -CHF 5.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.